Key facts
- NeuroBionics’s last known valuation is $33.3M (Dec 2025).
- It has raised $9.3M across 1 recorded rounds; the latest was Seed Round ($4.2M) in Nov 2025.
- Notable investors include Pioneer Fund, Mana Ventures, MedTech Innovator, Gaingels, Greentown Labs — 19 tracked in total.
- NeuroBionics has filed 1 Form D with the SEC, most recently Dec 2025 ($4.2M sold to 7 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for NeuroBionics
Funding rounds
1 roundsAbout NeuroBionics
Developer of a neural interface technology designed to enhance the integration of bioelectronics with the human body. The company offers features such as microscale, flexible bioelectronic fibers that incorporate electrical, chemical and optical capabilities to sense and modulate biological environments, enabling researchers and medical professionals to improve therapeutic interventions and develop treatments for neurological disorders while ensuring seamless interaction with biological systems.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2023
- Employees
- 10
- Website
- neurobionics.io/
- Ownership
- Privately Held (backing)
NeuroBionics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NeuroBionics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NeuroBionics in its N-PORT filings yet. We sweep new filings monthly.